Expert oncologist Zofia Piotrowska, MD, reviews the case of a patient managed with frontline chemotherapy after receiving a diagnosis of stage 4 NSCLC.
A 59-Year-Old Female With Lung Cancer
Comprehensive insight on the two novel, targeted agents approved for the management of EGFR exon 20–positive NSCLC following frontline therapy.
Practical advice regarding the selection and management of amivantamab or mobocertinib in patients diagnosed with EGFR exon 20–positive NSCLC.
Before closing out her discussion on novel therapy for EGFR exon 20–positive NSCLC, Zofia Piotrowska, MD, shares her hopes for future developments in care.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
